- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Grandiosity.
Displaying page 1 of 1.
EudraCT Number: 2008-001128-30 | Sponsor Protocol Number: BIIT001 | Start Date*: 2008-05-07 |
Sponsor Name:SE Dept. of Psychiatry and Psychotherapy | ||
Full Title: EFFICACY OF SERTINDOLE AS COMPARED TO OLANZAPINE OR RISPERIDONE ON PREATTENTIONAL AND ATTENTION-DEPENDENT FUNCTIONS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA. A COGNITIVE AND FMRI STUDY. | ||
Medical condition: schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005772-13 | Sponsor Protocol Number: AMISU_L_01008 | Start Date*: 2008-01-28 |
Sponsor Name:sanofi-aventis Zrt. | ||
Full Title: Comparative efficacy of amisulpride vs. risperidone on cognitive functions in patients with chronic schizophrenia. | ||
Medical condition: measure of overall cognitive functioning in chronic schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017971-10 | Sponsor Protocol Number: P05896 | Start Date*: 2011-10-12 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: An 8-week, placebo-controlled, double-blind, randomized, fixed-dose efficacy and safety trial of asenapine in adolescent subjects with schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003825-27 | Sponsor Protocol Number: 263CS201 | Start Date*: 2020-06-02 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004482-18 | Sponsor Protocol Number: R076477-SCH-4013 | Start Date*: 2008-01-03 | |||||||||||
Sponsor Name:Ortho-McNeil Janssen Scientific Affairs, LLC | |||||||||||||
Full Title: A blinded-initiation study of medication satisfaction in subjects with schizophrenia treated with paliperidone ER after suboptimal response to oral risperidone. | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000060-42 | Sponsor Protocol Number: D1001066 | Start Date*: 2017-03-15 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM-13496) in Acutely Psychotic Subjects with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000061-23 | Sponsor Protocol Number: D1001067 | Start Date*: 2017-03-15 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022307-22 | Sponsor Protocol Number: BergenPsychosisProject2 | Start Date*: 2011-04-14 | |||||||||||
Sponsor Name:Haukeland University Hospital, Division of Psychiatry | |||||||||||||
Full Title: The Bergen Psychosis Project 2 | |||||||||||||
Medical condition: Patients with schizophrenia and related non-affective psychotic disorders, corresponding to ICD-10 diagnoses F10.5-19.5, and F20-29. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012031-15 | Sponsor Protocol Number: 01KG0910 | Start Date*: 2009-11-19 | |||||||||||||||||||||
Sponsor Name:Technische Universitaet Muenchen, vertreten durch das Klinikum rechts der Isar | |||||||||||||||||||||||
Full Title: The switch study - efficacy of early antipsychotic switch versus maintenance in patients with schizophrenia poorly responding to two weeks of antipsychotic treatment | |||||||||||||||||||||||
Medical condition: Patients with a diagnosis of schizophrenia , schizophreniform disorder or schizoaffective disorder according to DSM-IV TR criteria; experiencing an acute episode of their illness | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) RO (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004006-26 | Sponsor Protocol Number: RGH-MD-20 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Gedeon Richter Plc. | |||||||||||||
Full Title: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to... | |||||||||||||
Medical condition: Adolescent Patients (13 to 17 years of age) with Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004132-33 | Sponsor Protocol Number: D1050304 | Start Date*: 2013-05-02 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features (Protocol No D1050304) | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018407-28 | Sponsor Protocol Number: P05688 | Start Date*: 2013-05-10 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine as an Active Control in Subjects With an Acute Ex... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001573-28 | Sponsor Protocol Number: Uni-Koeln-320 | Start Date*: 2007-11-26 |
Sponsor Name:Universität zu Köln | ||
Full Title: Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial. | ||
Medical condition: Persons at risk of being prodromally symptomatic of psychosis (PAR) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-001665-12 | Sponsor Protocol Number: KAR-012 | Start Date*: 2023-01-05 | |||||||||||
Sponsor Name:Karuna Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia. | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007800-27 | Sponsor Protocol Number: R092670-SCH-3004 | Start Date*: 2009-10-15 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate with Oral Risperidone in Adults with Recently-Diagnosed Schizophrenia... | |||||||||||||
Medical condition: Recently-Diagnosed Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006062-36 | Sponsor Protocol Number: NW-3509/008A/II/2020 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:Newron Pharmaceuticals S.p.A. | |||||||||||||
Full Title: A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 M... | |||||||||||||
Medical condition: Chronic schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) CZ (Completed) ES (Ongoing) RO (Ongoing) HU (Completed) PL (Completed) EE (Completed) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016715-38 | Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL | Start Date*: 2010-02-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
